Amanda Erickson Coleman
Veterinary cardiologist and first author of the design paper for TRIAD, the lifespan trial of rapamycin in pet dogs
Professor, Small Animal Medicine & Surgery (Cardiology Service), University of Georgia College of Veterinary Medicine · Adjunct Professor of Pathology · DVM, University of Florida (2007) · Diplomate, ACVIM (Cardiology)
Cardiology Service, University of Georgia College of Veterinary Medicine (Athens, Georgia, USA) ↗
Amanda Coleman is a veterinary cardiologist at the University of Georgia College of Veterinary Medicine, where she works in the Small Animal Medicine and Surgery department's Cardiology Service.
She is first author of the 2025 GeroScience design paper for TRIAD, a double-masked, randomized, placebo-controlled trial that will test whether rapamycin prolongs lifespan and improves healthspan measures in healthy middle-aged dogs from the Dog Aging Project. The paper sets out why and how the trial was built; it reports no results yet.
The timeline below follows Coleman's contribution gathered in this Atlas.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2025 | RT | Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project COL2025 First author of the design paper for TRIAD, a placebo-controlled trial testing rapamycin for lifespan in middle-aged dogs; no results yet. |
Co-authors in the Atlas
People with a profile here who share at least one study with Amanda Erickson Coleman.
- Kate E. Creevy Runs the veterinary side of the Dog Aging Project and leads TRIAD, the trial testing whether rapamycin extends lifespan in pet dogs
- Matt Kaeberlein Extended TOR/aging research from yeast to mice to pet dogs
Every researcher with a profile →
Thank you. Your answer was counted anonymously.
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.